Aiello Francesco, Durgin Jonathan, Daniel Vijaya, Messina Louis, Doucet Danielle, Simons Jessica, Jenkins James, Schanzer Andres
University of Massachusetts Medical School, Worcester, Mass.
University of Massachusetts Medical School, Worcester, Mass.
J Vasc Surg. 2017 Oct;66(4):997-1006. doi: 10.1016/j.jvs.2017.01.042. Epub 2017 Apr 5.
Fenestrated endovascular aneurysm repair (FEVAR) allows endovascular treatment of thoracoabdominal and juxtarenal aneurysms previously outside the indications of use for standard devices. However, because of considerable device costs and increased procedure time, FEVAR is thought to result in financial losses for medical centers and physicians. We hypothesized that surgeon leadership in the coding, billing, and contractual negotiations for FEVAR procedures will increase medical center contribution margin (CM) and physician reimbursement.
At the UMass Memorial Center for Complex Aortic Disease, a vascular surgeon with experience in medical finances is supported to manage the billing and coding of FEVAR procedures for medical center and physician reimbursement. A comprehensive financial analysis was performed for all FEVAR procedures (2011-2015), independent of insurance status, patient presentation, or type of device used. Medical center CM (actual reimbursement minus direct costs) was determined for each index FEVAR procedure and for all related subsequent procedures, inpatient or outpatient, 3 months before and 1 year subsequent to the index FEVAR procedure. Medical center CM for outpatient clinic visits, radiology examinations, vascular laboratory studies, and cardiology and pulmonary evaluations related to FEVAR were also determined. Surgeon reimbursement for index FEVAR procedure, related adjunct procedures, and assistant surgeon reimbursement were also calculated. All financial analyses were performed and adjudicated by the UMass Department of Finance.
The index hospitalization for 63 FEVAR procedures incurred $2,776,726 of direct costs and generated $3,027,887 in reimbursement, resulting in a positive CM of $251,160. Subsequent related hospital procedures (n = 26) generated a CM of $144,473. Outpatient clinic visits, radiologic examinations, and vascular laboratory studies generated an additional CM of $96,888. Direct cost analysis revealed that grafts accounted for the largest proportion of costs (55%), followed by supplies (12%), bed (12%), and operating room (10%). Total medical center CM for all FEVAR services was $492,521. Average surgeon reimbursements per FEVAR from 2011 to 2015 increased from $1601 to $2480 while the surgeon payment denial rate declined from 50% to 0%. Surgeon-led negotiations with the Centers for Medicare & Medicaid Services during 2015 resulted in a 27% increase in physician reimbursement for the remainder of 2015 ($2480 vs $3068/case) and a 91% increase in reimbursement from 2011 ($1601 vs $3068). Assistant surgeon reimbursement also increased ($266 vs $764). Concomitant FEVAR-related procedures generated an additional $27,347 in surgeon reimbursement.
Physician leadership in the coding, billing, and contractual negotiations for FEVAR results in a positive medical center CM and increased physician reimbursement.
开窗型血管内动脉瘤修复术(FEVAR)使以往超出标准器械使用指征范围的胸腹主动脉瘤和肾旁动脉瘤能够接受血管内治疗。然而,由于器械成本高昂且手术时间增加,FEVAR被认为会给医疗中心和医生带来经济损失。我们推测,由外科医生主导FEVAR手术的编码、计费及合同谈判,将提高医疗中心的贡献毛利(CM)并增加医生的报销费用。
在马萨诸塞大学纪念医疗中心复杂主动脉疾病中心,一位具有医疗财务经验的血管外科医生负责管理FEVAR手术的计费和编码,以实现医疗中心和医生的报销。对所有FEVAR手术(2011 - 2015年)进行了全面的财务分析,分析与保险状况、患者表现或所使用器械类型无关。确定了每例初次FEVAR手术及其所有相关后续手术(住院或门诊)在初次FEVAR手术前3个月和术后1年的医疗中心CM(实际报销减去直接成本)。还确定了与FEVAR相关的门诊就诊、放射学检查、血管实验室研究以及心脏和肺部评估的医疗中心CM。计算了初次FEVAR手术、相关辅助手术的医生报销费用以及助理外科医生的报销费用。所有财务分析均由马萨诸塞大学财务部门进行和裁决。
63例FEVAR手术的初次住院产生直接成本2,776,726美元,报销费用3,027,887美元,CM为正251,160美元。后续相关住院手术(n = 26)产生CM 144,473美元。门诊就诊、放射学检查和血管实验室研究产生额外CM 96,888美元。直接成本分析显示,移植物占成本的最大比例(55%),其次是耗材(12%)、床位(12%)和手术室(10%)。所有FEVAR服务的医疗中心总CM为492,521美元。2011年至2015年,每例FEVAR手术的平均医生报销费用从1601美元增加到2480美元,而医生付款拒绝率从50%降至0%。2015年外科医生与医疗保险和医疗补助服务中心的谈判导致2015年剩余时间医生报销费用增加27%(从每例2480美元增至3068美元),与2011年相比报销费用增加91%(从1601美元增至3068美元)。助理外科医生的报销费用也有所增加(从266美元增至764美元)。与FEVAR相关的同期手术为外科医生报销额外增加了27,347美元。
外科医生主导FEVAR的编码、计费及合同谈判可使医疗中心CM为正,并增加医生报销费用。